Medications

FDA approves first-in-class treatment for myasthenia gravis

(HealthDay)—Vyvgart (efgartigimod), a neonatal Fc receptor blocker (FcRn), was approved to treat generalized myasthenia gravis in adults who test positive for the anti-acetylcholine receptor (AChR) antibody, the U.S. Food ...

Health

Air pollution – a neglected cause of death 

In 2015, around 4.5 million people died prematurely from diseases attributed to ambient air pollution, including 237,000 children under the age of five from respiratory infections. This is the result of a study published ...

Diseases, Conditions, Syndromes

Protective immunity to seasonal coronaviruses may be short-lasting

The duration of protective immunity against SARS-CoV-2 may be short-lived, suggests a study investigating immunity to four other, similar coronaviruses. The findings from a case study of ten healthy subjects monitored over ...

Diseases, Conditions, Syndromes

A dose of 'wait-and-see' reduces unnecessary antibiotic use

Asking patients to take a 'wait-and-see' approach before having their antibiotic prescriptions filled significantly reduces unnecessary use, a University of Queensland study has shown.

page 2 from 16